No. Please read again. Nothing to do with DCVax.
Optune is too expensive to approve for general use in the UK and in Washington State, to name a few jurisdictions, and it has thus been rejected for general coverage in those jurisdictions or SOC for their patients. The standard GBM patients can't get it through the national healthcare system in the UK, except in special circumstances, because it's not considered worth the cost and questionable in terms of results. You can get it for only a small subset of GBM patients.
Optune is 21,000 FOREVER. It doesn't cure GBM. It slows tumor cell growth. You basically wait for tumor cells to grow and then it supposedly stops those cells from growing. It does not kill cancer cells.
2 years of Optune is $504,000. 5 years of Optune is $1,260,000.
DCVax for 2 years, prior to this inflationary spiral, and pre-commercial production, manually made, was around $220,000 I understand from other posts here previously, maybe less. For 2 years that is $9,167 per month. If the initial treatment goes as it did with the trial, and some patients live 30 months, their cost would be $7,333 per month. If they live 5 years, DCVax-L cost 3,667 per month.
Not counting visits to the doctors office for shots. In Europe and the UK, that cost is likely virtually free compared to the US.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
AI
